You are Correct BUT you have not taken into account that PAA are keeping Patients alive , unlike the current incumbent treatments only giving 2 to 3 months life extension ,,, that 2 to 3 months is at the end of life where regrettably MND Sufferers are already bed bound.
The MND community seems very tight with Facebook Forums and Regional Groups,,,, I couldn't see many MND Sufferers staying on the incumbent Medication once word within the Community spreads that MPL is delivering QOL Quality of Life..
With only two current Players in the field each with a rough 50% market share each and sales of $1.2B each then who ever brings MPL to market will surely steal the other Companies market share...
MPL as a Treatment for MND is not a Same Same drug with a different label,,, we are talking Disruptive Technology ...and that's Valuable NZT
PAA Price at posting:
10.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)